Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects

Trial Profile

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2007

At a glance

  • Drugs Fezakinumab; Fezakinumab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2007 Status changed from in progress to completed.
    • 09 Oct 2007 Status changed from recruiting to in progress.
    • 07 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top